ES2861048T3 - Derivados de 7-azaindol - Google Patents
Derivados de 7-azaindol Download PDFInfo
- Publication number
- ES2861048T3 ES2861048T3 ES16002047T ES16002047T ES2861048T3 ES 2861048 T3 ES2861048 T3 ES 2861048T3 ES 16002047 T ES16002047 T ES 16002047T ES 16002047 T ES16002047 T ES 16002047T ES 2861048 T3 ES2861048 T3 ES 2861048T3
- Authority
- ES
- Spain
- Prior art keywords
- salts
- atoms
- well
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC1(*)C=C(C(*)=C(*)N2*)C2=NC=C1 Chemical compound CC1(*)C=C(C(*)=C(*)N2*)C2=NC=C1 0.000 description 2
- QEKJMVPBZHTKHP-UHFFFAOYSA-N C[n]1ncc(-c2cnc3[nH]cc(-c4c[nH]c5c4ccnc5)c3c2)c1 Chemical compound C[n]1ncc(-c2cnc3[nH]cc(-c4c[nH]c5c4ccnc5)c3c2)c1 QEKJMVPBZHTKHP-UHFFFAOYSA-N 0.000 description 1
- AKIVVGUYCMQJHZ-UHFFFAOYSA-N Nc1ncc(-c2c[nH]c3c2cccn3)c2ccncc12 Chemical compound Nc1ncc(-c2c[nH]c3c2cccn3)c2ccncc12 AKIVVGUYCMQJHZ-UHFFFAOYSA-N 0.000 description 1
- GSIVMNXMHKSFRS-UHFFFAOYSA-N Nc1nccc2c1ccnc2Cl Chemical compound Nc1nccc2c1ccnc2Cl GSIVMNXMHKSFRS-UHFFFAOYSA-N 0.000 description 1
- NWBLNJFNNIXTNU-UHFFFAOYSA-N O=S(c1ccccc1)([n]1c(cncc2)c2c(-c2c[nH]c3c2cccn3)c1)=O Chemical compound O=S(c1ccccc1)([n]1c(cncc2)c2c(-c2c[nH]c3c2cccn3)c1)=O NWBLNJFNNIXTNU-UHFFFAOYSA-N 0.000 description 1
- PAPUJGVNROYWPB-UHFFFAOYSA-N c([nH]c1c2cccn1)c2-c1n[nH]c2c1cccc2 Chemical compound c([nH]c1c2cccn1)c2-c1n[nH]c2c1cccc2 PAPUJGVNROYWPB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011009961A DE102011009961A1 (de) | 2011-02-01 | 2011-02-01 | 7-Azaindolderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2861048T3 true ES2861048T3 (es) | 2021-10-05 |
Family
ID=45554609
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12701437.1T Active ES2608317T3 (es) | 2011-02-01 | 2012-01-09 | Derivados de 7-Azaindol |
| ES16002047T Active ES2861048T3 (es) | 2011-02-01 | 2012-01-09 | Derivados de 7-azaindol |
| ES14000623.0T Active ES2634643T3 (es) | 2011-02-01 | 2012-01-09 | Derivados de 7-azaindol |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12701437.1T Active ES2608317T3 (es) | 2011-02-01 | 2012-01-09 | Derivados de 7-Azaindol |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14000623.0T Active ES2634643T3 (es) | 2011-02-01 | 2012-01-09 | Derivados de 7-azaindol |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8981101B2 (OSRAM) |
| EP (3) | EP2746281B1 (OSRAM) |
| JP (1) | JP5891249B2 (OSRAM) |
| KR (1) | KR20140014158A (OSRAM) |
| CN (3) | CN105712991B (OSRAM) |
| AR (1) | AR085110A1 (OSRAM) |
| AU (1) | AU2012213775B2 (OSRAM) |
| BR (1) | BR112013019028A2 (OSRAM) |
| CA (2) | CA3082435A1 (OSRAM) |
| DE (1) | DE102011009961A1 (OSRAM) |
| EA (1) | EA201300873A1 (OSRAM) |
| ES (3) | ES2608317T3 (OSRAM) |
| HK (1) | HK1226394A1 (OSRAM) |
| IL (1) | IL227689A0 (OSRAM) |
| MX (1) | MX2013008212A (OSRAM) |
| SG (1) | SG192133A1 (OSRAM) |
| WO (1) | WO2012104007A2 (OSRAM) |
| ZA (1) | ZA201306542B (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8791113B2 (en) * | 2010-06-28 | 2014-07-29 | Merck Patent Gmbh | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer |
| DE102010053347A1 (de) * | 2010-12-03 | 2012-06-06 | Merck Patent Gmbh | 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren |
| DE102011009961A1 (de) * | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
| WO2013124025A1 (en) * | 2012-02-21 | 2013-08-29 | Merck Patent Gmbh | Furopyridine derivatives |
| DE102012019369A1 (de) | 2012-10-02 | 2014-04-03 | Merck Patent Gmbh | 7-Azaindolderivat |
| FR3001219A1 (fr) * | 2013-01-22 | 2014-07-25 | Centre Nat Rech Scient | Inhibiteurs de kinases |
| GB201303109D0 (en) | 2013-02-21 | 2013-04-10 | Domainex Ltd | Novel pyrimidine compounds |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| WO2014145051A1 (en) | 2013-03-15 | 2014-09-18 | Jiazhong Zhang | Heterocyclic compounds and uses thereof |
| TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
| JP6499282B2 (ja) | 2014-09-26 | 2019-04-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔａｎｋ結合キナーゼ阻害剤化合物として有用なアミノトリアジン誘導体 |
| CN107530302A (zh) * | 2015-03-04 | 2018-01-02 | 丹娜法伯癌症研究院 | Melk的水杨酸酯抑制剂和使用方法 |
| WO2016164641A1 (en) * | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| MX2017015357A (es) * | 2015-06-29 | 2018-03-16 | Merck Patent Gmbh | Compuestos inhibidores de serina/treonina-proteina cinasa (tbk)/inhibidor de cinasa de factor nuclear kappa-b subunidad epsilon (ikk-epsilon) y usos de los mismos. |
| WO2017106556A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Tank-binding kinase inhibitor compounds |
| US10894784B2 (en) | 2015-12-18 | 2021-01-19 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
| CN105906608B (zh) * | 2016-05-03 | 2018-10-19 | 中山大学 | 8-氨基喹啉-松果体素杂联体及其药物组合物 |
| WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
| GB201702947D0 (en) | 2017-02-23 | 2017-04-12 | Domainex Ltd | Novel compounds |
| US11180495B2 (en) * | 2017-06-19 | 2021-11-23 | Abbisko Therapeutics Co., Ltd. | Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof |
| US10717735B2 (en) | 2017-10-13 | 2020-07-21 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
| JP7478142B2 (ja) * | 2018-06-07 | 2024-05-02 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１阻害剤 |
| JP2021527125A (ja) * | 2018-06-07 | 2021-10-11 | ディサーム・セラピューティクス・インコーポレイテッドＤｉｓａｒｍ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｓａｒｍ１阻害剤 |
| KR20200046680A (ko) * | 2018-10-25 | 2020-05-07 | 한국과학기술원 | Pdk1 저해제를 포함하는 역노화 유도용 조성물 |
| WO2025016273A1 (zh) * | 2023-07-14 | 2025-01-23 | 拜西欧斯（北京）生物技术有限公司 | 异喹啉衍生物、包含其的药物组合物以及它们的用途 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
| JP2003500397A (ja) | 1999-05-19 | 2003-01-07 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Ｍｒｓ阻害剤としての２−ｎｈ−ピリドンおよびピリミドン |
| WO2005047266A1 (en) * | 2003-11-14 | 2005-05-26 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
| SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| EP2332940B1 (en) | 2004-03-30 | 2012-10-31 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
| SI2332940T1 (sl) * | 2004-03-30 | 2013-03-29 | Vertex Pharmaceuticals Incorporated | Azaindoli, uporabni kot inhibitorji jak in drugih protein-kinaz |
| FR2868422B1 (fr) * | 2004-03-31 | 2006-07-14 | Aventis Pharma Sa | Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| EP1773807A2 (en) * | 2004-06-14 | 2007-04-18 | Takeda San Diego, Inc. | Kinase inhibitors |
| US7709645B2 (en) | 2004-07-27 | 2010-05-04 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| WO2006050076A1 (en) * | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| US7511056B2 (en) | 2004-11-10 | 2009-03-31 | Eli Lilly And Company | TGF-β inhibitors |
| JP4954086B2 (ja) * | 2004-12-08 | 2012-06-13 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | １ｈ−ピロロ［２，３−ｂ］ピリジン |
| WO2006106326A1 (en) | 2005-04-06 | 2006-10-12 | Astrazeneca Ab | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors |
| US7541367B2 (en) | 2005-05-31 | 2009-06-02 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
| JP2007099640A (ja) * | 2005-09-30 | 2007-04-19 | Tsumura & Co | 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物 |
| CN101374839A (zh) * | 2006-01-17 | 2009-02-25 | 沃泰克斯药物股份有限公司 | 适用作詹纳斯激酶抑制剂的吖吲哚类 |
| CN102532134A (zh) * | 2006-01-17 | 2012-07-04 | 沃泰克斯药物股份有限公司 | 适用作詹纳斯激酶抑制剂的吖吲哚类 |
| DE102006012617A1 (de) * | 2006-03-20 | 2007-09-27 | Merck Patent Gmbh | 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
| EP2040546A4 (en) * | 2006-06-22 | 2009-12-23 | Merck & Co Inc | tyrosine kinase inhibitor |
| JP5642963B2 (ja) | 2006-06-30 | 2014-12-17 | スネシス ファーマシューティカルズ，インコーポレイティド | ピリジノニルｐｄｋ１阻害剤 |
| CA2673003A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Quinazolines for pdk1 inhibition |
| AU2008226844A1 (en) | 2007-03-13 | 2008-09-18 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1 |
| WO2008156726A1 (en) | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Inhibitors of janus kinases |
| DE102007028515A1 (de) | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
| AU2008317406B2 (en) | 2007-10-25 | 2013-07-18 | Merck Sharp & Dohme Corp. | Therapeutic compounds |
| RU2503676C2 (ru) | 2008-02-25 | 2014-01-10 | Ф.Хоффманн-Ля Рош Аг | Пирролопиразиновые ингибиторы киназы |
| DE102008025751A1 (de) * | 2008-05-29 | 2009-12-03 | Merck Patent Gmbh | 4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pyridin-2-ylamin-derivate |
| DE102008031517A1 (de) * | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
| DE102008038221A1 (de) * | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | 7-Azaindolderivate |
| CN101723936B (zh) | 2008-10-27 | 2014-01-15 | 上海睿星基因技术有限公司 | 激酶抑制剂及其在药学中的用途 |
| DE102009019962A1 (de) | 2009-05-05 | 2010-11-11 | Merck Patent Gmbh | 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate |
| CA2800176C (en) * | 2010-05-24 | 2018-08-28 | University Of Rochester | Bicyclic heteroaryl kinase inhibitors and methods of use |
| US8791113B2 (en) * | 2010-06-28 | 2014-07-29 | Merck Patent Gmbh | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer |
| DE102010053347A1 (de) | 2010-12-03 | 2012-06-06 | Merck Patent Gmbh | 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren |
| DE102011009961A1 (de) * | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
-
2011
- 2011-02-01 DE DE102011009961A patent/DE102011009961A1/de not_active Withdrawn
-
2012
- 2012-01-09 KR KR1020137022887A patent/KR20140014158A/ko not_active Withdrawn
- 2012-01-09 EP EP14000623.0A patent/EP2746281B1/de not_active Not-in-force
- 2012-01-09 EP EP12701437.1A patent/EP2670748B1/de not_active Not-in-force
- 2012-01-09 CA CA3082435A patent/CA3082435A1/en not_active Abandoned
- 2012-01-09 JP JP2013552124A patent/JP5891249B2/ja not_active Expired - Fee Related
- 2012-01-09 ES ES12701437.1T patent/ES2608317T3/es active Active
- 2012-01-09 CN CN201610048764.7A patent/CN105712991B/zh not_active Expired - Fee Related
- 2012-01-09 EP EP16002047.5A patent/EP3133074B1/de not_active Not-in-force
- 2012-01-09 US US13/983,083 patent/US8981101B2/en not_active Expired - Fee Related
- 2012-01-09 SG SG2013056726A patent/SG192133A1/en unknown
- 2012-01-09 BR BR112013019028A patent/BR112013019028A2/pt not_active IP Right Cessation
- 2012-01-09 WO PCT/EP2012/000067 patent/WO2012104007A2/de not_active Ceased
- 2012-01-09 ES ES16002047T patent/ES2861048T3/es active Active
- 2012-01-09 MX MX2013008212A patent/MX2013008212A/es not_active Application Discontinuation
- 2012-01-09 CN CN201280007145.3A patent/CN103502247B/zh not_active Expired - Fee Related
- 2012-01-09 ES ES14000623.0T patent/ES2634643T3/es active Active
- 2012-01-09 EA EA201300873A patent/EA201300873A1/ru unknown
- 2012-01-09 AU AU2012213775A patent/AU2012213775B2/en not_active Ceased
- 2012-01-09 CA CA2826051A patent/CA2826051C/en not_active Expired - Fee Related
- 2012-01-09 CN CN201610048667.8A patent/CN105732617B/zh not_active Expired - Fee Related
- 2012-02-01 AR ARP120100332A patent/AR085110A1/es not_active Application Discontinuation
-
2013
- 2013-07-29 IL IL227689A patent/IL227689A0/en active IP Right Grant
- 2013-08-30 ZA ZA2013/06542A patent/ZA201306542B/en unknown
-
2015
- 2015-02-06 US US14/616,113 patent/US9266887B2/en not_active Expired - Fee Related
-
2016
- 2016-01-05 US US14/987,946 patent/US9725446B2/en not_active Expired - Fee Related
- 2016-12-23 HK HK16114637.2A patent/HK1226394A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2861048T3 (es) | Derivados de 7-azaindol | |
| US8546390B2 (en) | 6-(pyrrolopyridinyl) pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and AIDS | |
| ES2436445T3 (es) | Derivados de 3-([1,2,3]triazol-4-il)-pirrolo[2,3-b]piridina | |
| JP6074364B2 (ja) | ５−（１，２，３−トリアゾール−４−イル）−７ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体 | |
| JP5718359B2 (ja) | ピロロ［２，３−ｂ］ピラジン−７−イルピリミジン化合物 | |
| CN103764651B (zh) | 适合治疗癌症疾病的7-氮杂吲哚衍生物 | |
| HK1226407A1 (en) | 7-azaindole derivatives | |
| HK1189220A (en) | 7-azaindole derivatives |